Medifast - Public Comps and Valuation Multiples

Medifast Overview

About Medifast

Medifast Inc is a old health and wellness company known for its habit-based and coach-guided lifestyle solution OPTAVIA, which provides people with a simple, yet comprehensive approach to address obesity and support a healthy life. OPTAVIA provides unparalleled coaching support along with community, tailored nutrition and healthy habits, and empowers people to master their weight loss journey through each stage of life. The company has access to GLP-1 medications where clinically appropriate. Medifast remains committed to its mission of offering Lifelong Transformation, Making a Healthy Lifestyle Second Nature.

Founded

1989

HQ

Employees

504

Website

medifastinc.com

Sectors

Consumer E-commerce
Vertical E-commerce
Health & Beauty

Financials

LTM Revenue $421M

LTM EBITDA $9.6M

EV

-$10.7M

Valuation Multiples

Multiples.vc

Valuation Multiples for 15K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Browse Valuation Multiples

Medifast Financials

As of September 2025, Medifast reported last 12-month revenue of $421M and EBITDA of $9.6M.

In the same period, Medifast generated $306M in LTM gross profit and -$5.7M in net income.

See Medifast valuation multiples based on analyst estimates

Medifast P&L

In the most recent fiscal year, Medifast reported revenue of $602M and EBITDA of $15.6M.

Medifast expects next 12-month revenue of XXX and NTM EBITDA of XXX

See Medifast valuation multiples based on analyst estimates

	LTM	NTM	Last FY	FY 2025	FY 2026	FY 2027
Revenue	$421M	XXX	$602M	XXX	XXX	XXX
Gross Profit	$306M	XXX	$445M	XXX	XXX	XXX
Gross Margin	73%	XXX	74%	XXX	XXX	XXX
EBITDA	$9.6M	XXX	$15.6M	XXX	XXX	XXX
EBITDA Margin	2%	XXX	3%	XXX	XXX	XXX
EBIT	-$8.6M	XXX	$2.9M	XXX	XXX	XXX
EBIT Margin	-2%	XXX	0%	XXX	XXX	XXX
Net Profit	-$5.7M	XXX	$2.1M	XXX	XXX	XXX
Net Margin	-1%	XXX	0%	XXX	XXX	XXX
Net Debt	XXX	XXX	n/a	XXX	XXX	XXX

Financial data powered by Morningstar, Inc.

.seo-only-financials-wrapper { position: static; left: auto; width: auto; height: auto; overflow: visible; }

Financial performance metrics for Medifast including revenue, profitability, and margin analysis across different time periods. The company reported last twelve months revenue of $421M. EBITDA for the last twelve months was $9.6M. In the most recent fiscal year, Medifast achieved $602M in revenue and $15.6M in EBITDA.
Financial Metric	Last Twelve Months (LTM)	Next Twelve Months (NTM)	Most Recent Fiscal Year	Current Fiscal Year (2025)	Next Fiscal Year (2026)	Two Years Forward (2027)
Total Revenue	$421M	Analyst estimates available to subscribers	$602M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Gross Profit	$306M	Analyst estimates available to subscribers	$445M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Gross Profit Margin	72.7% gross margin	Analyst estimates available to subscribers	73.8% gross profit margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBITDA (Earnings Before Interest, Taxes, Depreciation, Amortization)	$9.6M	Analyst estimates available to subscribers	$15.6M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBITDA Margin	2.3% EBITDA margin	Analyst estimates available to subscribers	2.6% EBITDA margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBIT (Earnings Before Interest and Taxes)	-$8.6M	Analyst estimates available to subscribers	$2.9M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBIT Margin	-2.0% EBIT margin	Analyst estimates available to subscribers	0.5% EBIT margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Income (Net Profit)	-$5.7M	Analyst estimates available to subscribers	$2.1M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Profit Margin	-1.3% net profit margin	Analyst estimates available to subscribers	0.3% net profit margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Debt Position	Detailed debt information available to subscribers	Detailed debt information available to subscribers	n/a	Detailed debt information available to subscribers	Detailed debt information available to subscribers	Detailed debt information available to subscribers

Financial Performance Summary for Medifast

This financial data table provides comprehensive performance metrics for Medifast, a company based in United States of America. The metrics include revenue, profitability measures, and operational efficiency indicators across multiple time periods.

Recent Performance Highlights

Medifast generated $421M in revenue over the last twelve months.
The company achieved $9.6M in EBITDA over the last twelve months.
Gross profit for the last twelve months was $306M.
Net income over the last twelve months reached -$5.7M.

Fiscal Year Performance

In the most recent fiscal year, Medifast reported $602M in total revenue.
Fiscal year EBITDA was $15.6M.
The company maintained a gross profit margin of 73.8% in the most recent fiscal year.
EBITDA margin for the fiscal year was 2.6%.
Net profit margin reached 0.3% in the most recent fiscal year.

This financial data is sourced from Morningstar, Inc. and represents the most recent available information for Medifast. Forward-looking estimates and detailed financial projections are available through our premium subscription service.

Medifast Stock Performance

Medifast has current market cap of $139M, and EV of -$10.7M.

Market Cap Evolution

Medifast Stock Data

As of October 23, 2025, Medifast's stock price is $13.

See Medifast trading valuation data

EV	Market Cap	Price 1D	Price 1M	Price 3M	Price 12M	EPS
-$10.7M	$139M	XXX	XXX	XXX	XXX	$-0.41

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Start Free Trial

Medifast Valuation Multiples

Medifast's trades at -0.0x EV/Revenue multiple, and -0.7x EV/EBITDA.

See valuation multiples for Medifast and 15K+ public comps

Medifast Financial Valuation Multiples

As of October 23, 2025, Medifast has market cap of $139M and EV of -$10.7M.

Equity research analysts estimate Medifast's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

Medifast has a P/E ratio of -24.4x.

	LTM	NTM	Last FY	FY 2025	FY 2026	FY 2027
Market cap (current)	$139M	XXX	$139M	XXX	XXX	XXX
EV (current)	-$10.7M	XXX	-$10.7M	XXX	XXX	XXX
EV/Revenue	-0.0x	XXX	-0.0x	XXX	XXX	XXX
EV/EBITDA	-1.1x	XXX	-0.7x	XXX	XXX	XXX
EV/EBIT	1.2x	XXX	-3.7x	XXX	XXX	XXX
EV/Gross Profit	-0.0x	XXX	n/a	XXX	XXX	XXX
P/E	-24.4x	XXX	66.4x	XXX	XXX	XXX
EV/FCF	-2.2x	XXX	-0.6x	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get Medifast Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Start Free Trial

Medifast Margins & Growth Rates

Medifast's last 12 month revenue growth is -15%

Medifast's revenue per employee in the last FY averaged $1.2M, while opex per employee averaged $0.9M for the same period.

Medifast's rule of 40 is -2% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Medifast's rule of X is -36% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

See operational valuation multiples for Medifast and other 15K+ public comps

Medifast Operational Valuation Multiples

	LTM	NTM	Last FY	FY 2025	FY 2026	FY 2027
Revenue Growth	-15%	XXX	n/a	XXX	XXX	XXX
EBITDA Margin	2%	XXX	3%	XXX	XXX	XXX
EBITDA Growth	-180%	XXX	n/a	XXX	XXX	XXX
Rule of 40	-2%	XXX	-13%	XXX	XXX	XXX
Bessemer Rule of X	XXX	XXX	-36%	XXX	XXX	XXX
Revenue per Employee	XXX	XXX	$1.2M	XXX	XXX	XXX
Opex per Employee	XXX	XXX	$0.9M	XXX	XXX	XXX
S&M Expenses to Revenue	XXX	XXX	n/a	XXX	XXX	XXX
G&A Expenses to Revenue	XXX	XXX	n/a	XXX	XXX	XXX
R&D Expenses to Revenue	XXX	XXX	n/a	XXX	XXX	XXX
Opex to Revenue	XXX	XXX	73%	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics

Pharma Analytics

Private Equity

ERP Software

Developer Tools

Consumer SaaS

Streaming Platforms

Explore Valuation Multiples by Industry

Start Free Trial